BIOLIGHT(SZ:300246)2025-01-17 11:34Financial Performance Outlook - The company expects a net loss for 2024, estimated between RMB 45 million and RMB 67.5 million, compared to a loss of RMB 65.1851 million in 2023[4] - The expected non-recurring losses for 2024 are projected to be between RMB 67.9 million and RMB 90.4 million, compared to RMB 81.5033 million in 2023[4] - The estimated impact of non-recurring gains on net profit for 2024 is approximately RMB 22.95 million, primarily from government subsidies[6] Reasons for Performance Decline - The main reasons for the performance decline include increased competition, adjustments in the business model, and a decrease in orders, leading to reduced revenue[6] - Management and financial expenses have increased compared to the previous year, impacting overall profitability[6] Strategic Initiatives - The company plans to enhance its R&D efforts for new products and actively expand its market presence[6] - There will be a focus on improving internal management and implementing cost-reduction measures to enhance core competitiveness and profitability[6] Investor Advisory - Investors are advised to make cautious decisions and be aware of investment risks[9] - The performance forecast has not been audited by an external accounting firm, and the final financial data will be disclosed in the annual report[8] Announcement Details - The announcement was made by the board of directors on January 17, 2025[11]